The Optimis Fusion integrated laser platform from Quantel Medical has received CE Mark approval. The system is a combination of advanced selective laser trabeculoplasty photoregeneration therapy with traditional YAG photodisruption treatment for treating both cataract and glaucoma.

The integrated laser platform system's unique selective laser trabeculoplasty mode incorporates the most advanced laser technology available to target melanin-rich cells, which absorb the laser energy and induce a healing response that improves the function of the trabecular meshwork. Laser energy is delivered in short, fixed pulses over a large homogeneous spot size, which results in no thermal damage. With this gentle delivery, no permanent destruction to the trabecular meshwork occurs, and the structures are left intact. Selective laser trabeculoplasty can then be repeated if necessary.

The system's YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy. A Gaussian laser beam profile allows for precise laser delivery using minimum energy levels, to avoid side effects such as lens pitting. An advanced two-point aiming beam allows for precise tissue targeting, to achieve fast and accurate targeting of the capsule. An adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

"We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design," said Jean-Marc Gendre, CEO of Quantel Medical.

Quantel has announced that it will immediately begin commercialization of the system in al CE Mark-approved countries and FDA approval is expected in 2014.